 Hi, how's everybody doing today? I'm your host, Rich from Rich TV Live with our very special guest, the CEO of Valeo Pharma, Steve Saviek, with some huge news today, some huge breaking news today. How are you doing today, Steve? Very good, Rich. Nice to be back on your show. Love having you on the show, and I want to talk about the big breaking news. You've announced this morning that the Montreal Heart Institute will be conducting a trial on COVID-19 with your Hesperco capsules. Can you tell us what the medicinal, medical ingredient, Hesperidine, contained in the capsule does exactly and where it comes from? Well, Hesperidine is derived from the crust of citrus fruit. It's processed into a specific formulation of pure Hesperidine. It has over 20 years shown some very interesting properties in terms of viral defense, specific on coronaviruses which are around us and have been for the last 20 years in various variants. It does things or is thought to do three things. One is reduced infection. Second is to reduce replication. And third is to support your immune system against the inflammatory response that comes from your body. Three modes of action and it's, again, shown in over 150 scientific journals. A lot of research done on Hesperidine over the last 20 years since the original outbreak of serious SARS-CoV-1 back in 2002. Fantastic. And how did you get the Montreal Heart Institute to be interested in conducting a clinical trial on Hesperidine? We partnered up, we value a farmer last March with a company that we've known for quite some time called Ingenu Farms. And Ingenu Farms is a small biotech company in Montreal. They did a lot of the initial groundwork on finding Hesperidine and looking at all the scientific literature. They put together quite a, I guess, an in-depth scientific proposal that the Montreal Heart Institute reviewed and accepted as being very interesting and warranting further research. Value as part of the equation was putting together the formulations, manufacturing the product, helping with the Health Canada submission, and ultimately commercializing the product as we're doing now. The scientists at your development partner Agnew Farmer, which you just mentioned, have done extensive and exhaustive scientific research. And it seems like Hesperidine has all these great anti-inflammatory and antioxidant properties with a great safety profile. It almost looks too good to be true. Why haven't we seen other pharma companies interested in pursuing a trial on Hesperidine? Well, as the CEO of Ingenu Farmer, as Juan to say, you couldn't manufacture a product that had these properties. You stumble upon one. And it's really sort of just a done haphazardly in the sense that there was a lot of screening of molecules when the original SARS outbreak happened in early 2002. This was one product that just drew attention because of its properties. Why doesn't Big Pharma go after this? I would say it's a natural product. It has probably lower pricing potential than Big Pharma would typically want to see. And those are the main reasons. This is a very inexpensive product. Dollar a day, we call it, and two capsules provide you with 1,000 milligrams, which is a health Canada's recommended daily dose. I think that's great. A dollar a day to maintain your health is a great preventative solution and option for Canadians and Americans and potentially investors. And potentially patients all over the world for your company. Now, why should people be interested in taking or continuing to take Hesperco with the vaccines getting rolled out to more and more people? Well, there's a number of reasons. Number one is certainly prior to, I mean, this is not a product that we recommend. You take only if you feel ill, although a lot of people will. As you would typically take other, you know, ingredients when you feel symptoms of some cold or what have you. You could take this prior. We believe it has enough other properties that are beneficial to the body in addition to potentially preventing the viral load or the amount of virus from entering your body. It has that property. The second is, you know, the vaccines are absolutely the way people should go. I mean, clearly, but not everyone's going to be taking a vaccine. And even if you take the vaccines, there is this element of, you know, efficacy, which has seemed to be in a 90 plus percent range. So there still is a chance that you will get, you could get infected by the virus. The second is the vaccine is not a for life kind of vaccine. It has to be taken on a regular basis. That's the expectation of people that the vaccine will. So I would say primarily people should take the vaccine while you're waiting for the vaccine. Take a spherical, but also I think take a spherical against other viruses that could be potentially infectious to the body. So it's really something that is has a lot of different properties that are beneficial to the body and patients, regardless of being vaccinated or not should continue in our view to. And I certainly expect to do that as well as a lot of our colleagues continue to take a spherical. So what we're noticing now, and we're seeing it in other places all over the world, is that there's different variants of the virus. So will has parody and work on those variants as well? The it's early to tell right now, but what we believe and what ingenue believes more specifically than they're doing a lot of the work on it is the virus needs to enter your body. And regardless of the variants, it enters your body through the same mechanism. So the expectation and through the same portal, which is your ACE2 receptors, which are commonly in your lungs. So as long as there is a prevention aspect, which is what is parodying, one of the properties is parodying is thought to have. It would, you know, the theory is again, it's theory because these virus variants are so new is that they're, but the act, we know they act in the same way that we should have the same kind of beneficial effect to patients. Wow. That would be incredible because from what I'm hearing, a lot of the vaccines are not working with some of these new variants. So if your product does, then that will be a huge breakthrough for the company. So that'll be exciting to see how that rolls out. Now you mentioned that Hasperko will be available in retailers. When will it go on sale and which retailers can we expect to see it in? Well, currently it is on sale. It is for sale online through our own website, hasperko.com, but also through amazon.ca and Amazon quite a bit of it since we launched late November. In terms of the traditional bricks and mortar retailers, you could expect to see Rexall, Shoppers, Drugmars, these type of retailers having availability of this product in the coming weeks. We've been in discussion with all of them. Marketing plans are being put together and programs to, in terms of making the product visible to consumers are all in the works. So I can't give you definitive date, but I would continue to tell you, if you want to own the product or buy it today online, but by all means go to your local pharmacy and ask for it or at least put yourself on a list that as soon as they get it, you'll be made aware and you can pick it up at these pharmacies. We will be going into the U.S. also probably early March. Initially again through Amazon, U.S. retail market is much more fragmented than the Canadian market. A lot of different banners, a lot of different stores out there. So the rollout is we're discussing that with a potential U.S. partner in terms of how that's going to happen. But we've actually manufactured U.S. labeled products. So that's the expectation is we'll be launching U.S. shortly. That's going to be huge for Valeo Pharma. I'm excited to see what happens with you guys when that happens. Typically when we see companies move into the U.S., it's just an explosion of revenue and explosion of growth and typically price appreciation as well. So that'll be exciting to see. Now how long, and I know you mentioned, you can't really mention exactly, but just to give us an estimate, how long will the study last? And when can we expect to see some results? The study has a total number of patients forecasted of about 216. It's got two arms. So one is known as the placebo arm. So they're taking essentially a sugar capsule versus asperidine capsule. So the research can identify the benefits of asperidine over the placebo. So a typical clinical practice. There's a lot of cases, as you know, in Quebec, and therefore a lot of patients potentially to recruit from. Our expectation is probably 90 to 120 days. The trial should be complete at which point there'd be some type of information. It could go longer than that. It's very unique. It's a distance trial. So in other words, patients don't go to the Montreal Heart Institute. They enroll, and all of the documentation and product is actually shipped to them at their home or office, but for not probably more so home. So this is kind of a new way of doing some clinical trials where it's harder to get people to actually come into a facility. So we're trying to do it at distance. Looking forward to the results, I think a lot of people are. I'm excited about seeing what the results are going to look like, and I know our community is. Now, our community has been following Valeo Pharma for quite some time now, and it's been a success story so far. And we love revenue and revenue growth. We love tight float stocks. We love growing companies, and you guys literally fit the bill. Now, can you provide us with a revenue forecast from the sales of Hesperco and what it could represent to the bottom line of Valeo Pharma? Okay, we'll just give you a bit of background. So we finished our last fiscal year, ending October with approximately $8 million in revenue that we're forecasting that to grow to about $20 million to $25 million this year. Wow. That's from our existing products that are continuing to grow, and two big revenue drivers that we foresee, which is the Hesperco being one. The other is Redesca, our low molecular weight heparin that we're launching late spring or early summer, which we think will have a top line sort of peak sales of in the 30 plus million range for Redesca. Hesperco is very difficult to forecast. I mean, our forecasts are relatively low, six to 10 million. They could be, that number could be multiplied by many, but we're trying to be as conservative as we can in terms of our investors. If we do 20 to 25 this year with another probably 20 million addition year after, we believe we're well on our way to being a $60-80 million revenue company in the next three, four years, potentially sooner. And a lot of it is on the back, as I say, of Redesca, Hesperco, but we have a number of other products. Our Parkinson's drug that we launched a year and a half ago is starting to do well and some of our other injectables that we've launched during the course of last year. So people can expect to see that $20, $25 million range and profitability by the end of this fiscal year. Wow, I'm really excited to see everything unfold. And guys, remember Rich DV Live is strictly for education and entertainment purposes. Always do your due diligence. Always do your research before you invest in anything that we discuss or talk about here in Rich DV Live. If you liked the video, please smash the like button, comment down below, share the video everywhere, and subscribe. And feel free to contact Steve yourself. Get in contact with the company if you have any questions. If you're an investor and you'd like to learn more, Steve is very willing to communicate with shareholders. And thank you guys for watching. If you're not winning, you're not watching. We bring in the winners and we bring them to you first. I think this is a company that's undervalued, underappreciated, underexposed. When you look at big pharma companies, you see these huge billion-dollar giants. This is a company that I think has a chance to one day grow to become a big pharma company, but you're getting an opportunity to literally get in in the early stages while they're still a microcap stock. So in my opinion, huge upside for value of pharma and we get an opportunity to position ourselves and grow with the company. Thank you so much for your time today, Steve. Congratulations on all your success thus far. And we'll be watching along the way. Look forward to being back with updates and more news. Yeah. And like I said, if you ever have any big breaking news like this that you'd like to introduce to our community, we'd love to invite you back on our show at your convenience. Keep up all the great work and thank you for joining us today. Thank you. Thank you, Steve. Thank you guys for watching. Have yourselves a great day.